ClinicalTrials.gg
RecruitingNCT06439927Updated Nov 5, 2024

New Method to Close Nasal Septal Perforation

An interventional study of Polycaprolactone nasal mesh in Nasal Perforated Septum, sponsored by Helwan University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 58 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Helwan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 58 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate if a 3-dimensional fabricated nasal mesh works to close nasal septal perforations. Under general anesthesia, during nasal septal perforation repair surgery, the investigator will place the mesh between the elevated mucoperichondrial flaps opposite the site of the perforation and confirm its original position at both sides under nasal endoscope. Endoscopic examination for septal mucosa status will be done monthly for a three months follow up period.

02

Conditions studied

  • Nasal Perforated Septum

Keywords

  • nasal septal perforation
03

In context

Lead sponsor

Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing nasal septal perforation repair surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergy to polycaprolactone.
  • Pregnancy or lactation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Polycaprolactone nasal mesh

    Device: Polycaprolactone nasal mesh

Interventions

  • DevicePolycaprolactone nasal mesh

    a 3-dimensional fabricated Polycaprolactone nasal mesh

06

What researchers measure

Primary outcomes

  1. Mean Change in Post-operative healing of septal perforation

    Endoscopic evaluation of nasal septal mucosa status will be classified as complete bilateral healing, complete unilateral healing, no healing, and perforation.

    Time frame: for a three months follow up period

Secondary outcomes

  1. Postoperative complications

    The following complications will be evaluated on a present/absent basis:hematoma-infection-allergy

    Time frame: for a three months follow up period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Sep 2025, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 3, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Dec 2025
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06439927
Lead sponsor
Helwan University
Responsible party
Mohamed Hossam Sebaey (Assistant lecturer of otorhinolaryngology, Helwan University) — Principal investigator
First posted
Jun 3, 2024
Start date
Aug 1, 2024
Primary completion
Sep 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 5, 2024

Study contacts

Mohamed H Sebaey, Master degree
Contact
mohamed.h757@hotmail.com
01008306356
Mohamed H Sebaey, master degree
principal investigator · Helwan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion